No Data
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
GENSCRIPT BIO (01548.HK) exercises the conversion rights of the convertible Bonds issued by Probio Cayman.
Gelonghui, December 20 - GENSCRIPT BIO (01548.HK) announced that the company's indirect non-wholly-owned subsidiary, Probio Technology Limited ("Probio Cayman"), has completed Series A financing and that the company has subscribed to the convertible Bonds issued by Probio Cayman. On December 20, 2024, based on the convertible Bonds instrument dated August 24, 2021 (as amended by the revised agreement dated December 18, 2024), the company will exercise its rights to invest $70 million.
Is Genscript Biotech (HKG:1548) Using Too Much Debt?
GenScript Announces 4th Annual Biotech Global Forum in San Francisco
Genscript Bio (01548.HK): Legend Biotech announces the release of a report at the 2024 ASH annual meeting.
On December 10, Guolonghui reported that GENSCRIPT BIO (01548.HK) announced that on December 10, 2024 (before the Hong Kong trading session on December 10), Legend Biotech released a press release, announcing the latest data from the Phase 3 study CARTITUDE-4. The study results indicate that in patients with relapsed or lenalidomide-refractory multiple myeloma who have previously received at least first-line treatment (including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD)), compared to standard therapy (pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide...
FDA Grants IND Approval to Base Therapeutics' Base-Edited NK Cell Therapy, Powered by GenScript's CGMP SgRNA and CytoSelect Platform
Genscript Biotech Corporation's (HKG:1548) P/S Is Still On The Mark Following 29% Share Price Bounce
